HDAC6 Links B-ALL Motility to Relapse

Company CINVESTAV (Center for Research and Advanced Studies of the National Polytechnic Institute) Event Type Preclinical Research Findings Modality Small-molecule / genetic target validation (HDAC6 inhibition) Asset HDAC6-selective chemistry (research-stage, not a named clinical asset) Target HDAC6 (via cortactin-dependent cytoskeletal remodeling) Disease Area B-cell Acute…